Fox Rena K, Muniraj Thiruvengadam
Division of General Internal Medicine, Department of Medicine, University of California, San Francisco School of Medicine, 1545 Divisadero St, Ste 307, San Francisco, CA, USA.
Section of Digestive Diseases, Department of Medicine, Yale University School of Medicine, 333 Cedar Street, 1080 LMP, New Haven, CT 06520-8019, USA.
Med Clin North Am. 2016 Jul;100(4):827-50. doi: 10.1016/j.mcna.2016.03.009.
Several key areas in gastroenterology pharmacotherapy are rapidly evolving, including the treatment of hepatitis C virus (HCV), irritable bowel syndrome, gastroesophageal reflux disease (GERD) and peptic ulcer disease. HCV treatment has radically changed in the past 2 years and now most patients are treatment candidates and have a high likelihood of permanent cure. Pharmacotherapy is now first-line treatment for patients with moderate to severe symptoms of irritable bowel syndrome. Proton pump inhibitors (PPIs) are the mainstay of therapy in gastric and duodenal ulcers and GERD, although long-term use carries the risk of several side effects that should be considered.
胃肠病药物治疗的几个关键领域正在迅速发展,包括丙型肝炎病毒(HCV)、肠易激综合征、胃食管反流病(GERD)和消化性溃疡病的治疗。在过去两年中,HCV治疗发生了根本性变化,现在大多数患者都是治疗对象,并且有很高的永久治愈可能性。药物治疗现在是中重度肠易激综合征患者的一线治疗方法。质子泵抑制剂(PPI)是胃溃疡、十二指肠溃疡和GERD治疗的主要药物,尽管长期使用存在一些应予以考虑的副作用风险。